Baxter International Inc. has reported its third-quarter 2025 results, showing a 5% increase in sales from continuing operations, totaling approximately $2.84 billion. This represents a 2% increase on an operational basis. The company reported a third-quarter U.S. GAAP diluted earnings per share (EPS) from continuing operations of ($0.10), while the adjusted diluted EPS from continuing operations was $0.69, reflecting a significant improvement.
Breaking down the sales performance by region, U.S. sales from continuing operations increased by 3% on a reported basis, while international sales from continuing operations saw an 8% increase on a reported basis and a 5% increase on an operational basis.
In terms of segment results, the medical products & therapies sales declined by 1% on both a reported and operational basis, primarily driven by reduced sales within the infusion therapies & technologies division. On the other hand, healthcare systems & technologies sales increased by 3% on a reported basis and 2% on an operational basis. The pharmaceuticals segment also saw a 7% increase in sales on both reported and operational bases.
Baxter International Inc. highlighted several recent developments, including the launch of the Welch Allyn Connex 360 vital signs monitor, which is the company's next-generation patient monitoring device. Additionally, the company was awarded a gold level resiliency badge from the Healthcare Industry Resilience Collaborative (HIRC) in several categories, becoming the first manufacturer to earn this distinction across these categories.
Looking ahead, Baxter now expects sales growth from continuing operations of 4% to 5% on a reported basis for the full year 2025, with an operational basis sales growth expectation of 1% to 2%. The company also provided its financial outlook for the fourth quarter of 2025, expecting sales growth from continuing operations of approximately 2% on a reported basis and a decline of approximately 2% on an operational basis. Adjusted earnings from continuing operations, before special items, are expected to be in the range of $0.52 to $0.57 per diluted share for the fourth quarter.
This performance comes as Andrew Hider joined the company as president and CEO, focusing on driving continuous improvement and sustainable growth, and creating shareholder value. Following these announcements, the company's shares moved -1.93%, and are now trading at a price of $22.42. For more information, read the company's full 8-K submission here.
